Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2018

Open Access 01-12-2018 | Research

SGEF is a potential prognostic and therapeutic target for lung adenocarcinoma

Authors: Qian Chen, Xiao Lu, Quan-Xing Liu, Dong Zhou, Yuan Qiu, Ji-Gang Dai, Hong Zheng

Published in: World Journal of Surgical Oncology | Issue 1/2018

Login to get access

Abstract

Background

SH3-containing guanine nucleotide exchange factor (SGEF), a RhoG-specific guanine nucleotide exchange factor (GEF), was consider as a key signal that determines cancer cell invasion. Although SGEF has been considered to highly express in glioma and prostate cancer. However, it is not well illustrated in LAC.

Methods

In this experiment, expression of SGEF was detected in 92 LAC and corresponding normal tissue samples by immunohistochemistry. In addition, we evaluated the invasion and migration of lung adenocarcinoma cells by the gain and loss of SGEF expression. Furthermore, RhoG activity was measured by GST pull-down assay.

Results

SGEF is highly expressed in LAC tissues than in normal lung tissues and was associated with the TNM stage. Lung adenocarcinoma patients with low SGEF subgroup had longer overall survival compared to those with high expression. Furthermore, univariate analysis showed that SGEF expression was an independent prognostic factor for overall survival in lung adenocarcinoma. Silencing of SGEF effectively suppressed the invasion and migration of human lung adenocarcinoma cells in vitro by inhibiting RhoG activity, and over-expression of SGEF could reverse this phenomena.

Conclusion

SGEF is a novel prognostic target in human lung adenocarcinoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
2.
go back to reference Takamochi K, Oh S, Matsunaga T, Suzuki K. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma. J Thorac Cardiovasc Surg. 2017;153:1768–74.e1.CrossRef Takamochi K, Oh S, Matsunaga T, Suzuki K. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma. J Thorac Cardiovasc Surg. 2017;153:1768–74.e1.CrossRef
5.
go back to reference Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev. 2002;16:1587–609.CrossRefPubMed Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev. 2002;16:1587–609.CrossRefPubMed
6.
7.
go back to reference Ellerbroek SM, Wennerberg K, Arthur WT, Dunty JM, Bowman DR, Demali KA, Der C, Burridge K. SGEF, a RhoG guanine nucleotide exchange factor that stimulates macropinocytosis. Mol Biol Cell. 2004;15:3309–19.CrossRefPubMedPubMedCentral Ellerbroek SM, Wennerberg K, Arthur WT, Dunty JM, Bowman DR, Demali KA, Der C, Burridge K. SGEF, a RhoG guanine nucleotide exchange factor that stimulates macropinocytosis. Mol Biol Cell. 2004;15:3309–19.CrossRefPubMedPubMedCentral
8.
go back to reference Rehak S. Czech and Slovak professors of ophthalmology. Cesk Oftalmol. 1987;43:51–7.PubMed Rehak S. Czech and Slovak professors of ophthalmology. Cesk Oftalmol. 1987;43:51–7.PubMed
9.
go back to reference Liu QX, Zheng H, Deng XF, Zhou D, Dai JG. Status of the Parkinson's disease gene family expression in non-small-cell lung cancer. World J Surg Oncol. 2015;13:238.CrossRefPubMedPubMedCentral Liu QX, Zheng H, Deng XF, Zhou D, Dai JG. Status of the Parkinson's disease gene family expression in non-small-cell lung cancer. World J Surg Oncol. 2015;13:238.CrossRefPubMedPubMedCentral
10.
go back to reference Xue M, Tao W. Upregulation of MUC1 by its novel activator 14-3-3zeta promotes tumor invasion and indicates poor prognosis in lung adenocarcinoma. Oncol Rep. 2017;38:2637–46.CrossRefPubMedPubMedCentral Xue M, Tao W. Upregulation of MUC1 by its novel activator 14-3-3zeta promotes tumor invasion and indicates poor prognosis in lung adenocarcinoma. Oncol Rep. 2017;38:2637–46.CrossRefPubMedPubMedCentral
11.
go back to reference Wang H, Wu R, Yu L, Wu F, Li S, Zhao Y, Li H, Luo G, Wang J, Zhou J. SGEF is overexpressed in prostate cancer and contributes to prostate cancer progression. Oncol Rep. 2012;28:1468–74.CrossRefPubMed Wang H, Wu R, Yu L, Wu F, Li S, Zhao Y, Li H, Luo G, Wang J, Zhou J. SGEF is overexpressed in prostate cancer and contributes to prostate cancer progression. Oncol Rep. 2012;28:1468–74.CrossRefPubMed
12.
go back to reference Visentini M, Conti V, Cagliuso M, Siciliano G, Scagnolari C, Casato M, Fiorilli M. Persistence of a large population of exhausted monoclonal B cells in mixed cryoglobuliemia after the eradication of hepatitis C virus infection. J Clin Immunol. 2012;32:729–35.CrossRefPubMed Visentini M, Conti V, Cagliuso M, Siciliano G, Scagnolari C, Casato M, Fiorilli M. Persistence of a large population of exhausted monoclonal B cells in mixed cryoglobuliemia after the eradication of hepatitis C virus infection. J Clin Immunol. 2012;32:729–35.CrossRefPubMed
13.
go back to reference Goicoechea S, Zinn A M, Awadia SS, Snyder K, Garcia-Mata R. A RhoG-mediated signaling pathway that modulates invadopodia dynamics in breast cancer cells. J Cell Sci. 2017;130:1064–77.PubMed Goicoechea S, Zinn A M, Awadia SS, Snyder K, Garcia-Mata R. A RhoG-mediated signaling pathway that modulates invadopodia dynamics in breast cancer cells. J Cell Sci. 2017;130:1064–77.PubMed
14.
go back to reference Ridley AJ, Comoglio PM, Hall A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol. 1995;15:1110–22.CrossRefPubMedPubMedCentral Ridley AJ, Comoglio PM, Hall A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol. 1995;15:1110–22.CrossRefPubMedPubMedCentral
15.
go back to reference Polat R, Peker K, Guloksuz CT, Ergil J, Akkaya T. Comparison of the postoperative analgesic effects of paracetamol-codeine phosphate and naproxen sodium-codeine phosphate for lumbar disk surgery. Kaohsiung J Med Sci. 2015;31:468–72.CrossRefPubMed Polat R, Peker K, Guloksuz CT, Ergil J, Akkaya T. Comparison of the postoperative analgesic effects of paracetamol-codeine phosphate and naproxen sodium-codeine phosphate for lumbar disk surgery. Kaohsiung J Med Sci. 2015;31:468–72.CrossRefPubMed
16.
go back to reference Schendel SA, Peauroi J. Magnesium-based bone cement and bone void filler: preliminary experimental studies. J Craniofac Surg. 2009;20:461–4.CrossRefPubMed Schendel SA, Peauroi J. Magnesium-based bone cement and bone void filler: preliminary experimental studies. J Craniofac Surg. 2009;20:461–4.CrossRefPubMed
17.
go back to reference Barrio-Real L, Kazanietz MG. Rho GEFs and cancer: linking gene expression and metastatic dissemination. Sci Signal. 2012;5:e43.CrossRef Barrio-Real L, Kazanietz MG. Rho GEFs and cancer: linking gene expression and metastatic dissemination. Sci Signal. 2012;5:e43.CrossRef
18.
go back to reference Wang H, Li S, Li H, Li C, Guan K, Luo G, Yu L, Wu R, Zhang X, Wang J, Zhou J. SGEF enhances EGFR stability through delayed EGFR trafficking from early to late endosomes. Carcinogenesis. 2013;34:1976–83.CrossRefPubMed Wang H, Li S, Li H, Li C, Guan K, Luo G, Yu L, Wu R, Zhang X, Wang J, Zhou J. SGEF enhances EGFR stability through delayed EGFR trafficking from early to late endosomes. Carcinogenesis. 2013;34:1976–83.CrossRefPubMed
19.
go back to reference Wang H, Li S, Li H, Wang P, Huang F, Zhao Y, Yu L, Luo G, Zhang X, Wang J, Zhou J. Grb2 interacts with SGEF and antagonizes the ability of SGEF to enhance EGF-induced ERK1/2 activation. Mol Cell Biochem. 2014;389:239–47.CrossRefPubMed Wang H, Li S, Li H, Wang P, Huang F, Zhao Y, Yu L, Luo G, Zhang X, Wang J, Zhou J. Grb2 interacts with SGEF and antagonizes the ability of SGEF to enhance EGF-induced ERK1/2 activation. Mol Cell Biochem. 2014;389:239–47.CrossRefPubMed
Metadata
Title
SGEF is a potential prognostic and therapeutic target for lung adenocarcinoma
Authors
Qian Chen
Xiao Lu
Quan-Xing Liu
Dong Zhou
Yuan Qiu
Ji-Gang Dai
Hong Zheng
Publication date
01-12-2018
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2018
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-018-1331-8

Other articles of this Issue 1/2018

World Journal of Surgical Oncology 1/2018 Go to the issue